Antibe Therapeutics: Top 10 Undervalued Biotechnology Industry Stocks (ATE)
Antibe Therapeutics is now ranked among the top 10 undervalued stocks in the Biotechnology industry on the Toronto Stock Exchange or TSX Venture Exchange.
- A stock is considered undervalued if it trades at a discount to its valuation – a calculation used to determine the intrinsic (true) worth of a company
- Valuation methodology provided by Stockcalc (see below)
Biotechnology: Biotech and biopharmaceutical companies engaged in research, discovery, development, and production of innovative drug and drugrelated technologies.
Stocks in this category are held primarily for capital appreciation.
| Symbol | Name | Close Price ($) | Valuation ($) | Difference | Average Vol (30D) | Market Cap ($M) | Yield (%) | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
| BTI | Bioasis Technologies | 0.01 | 0.02 | 0.01 (219.1%) | 262 | 0.4 | 0.0 | 0.0 |
| ATE | Antibe Therapeutics | 0.29 | 0.60 | 0.31 (103.9%) | 182607 | 15.5 | 0.0 | 0.0 |
| QPT | Quest PharmaTech | 0.03 | 0.06 | 0.03 (83.7%) | 8146 | 5.1 | 0.0 | 0.0 |
| RP | RepliCel Life Sciences | 0.06 | 0.09 | 0.04 (67.4%) | 3.4 | 0.0 | 0.0 | |
| AEZS | AEterna Zentaris | 2.79 | 4.31 | 1.52 (54.6%) | 2148 | 13.5 | 0.0 | 0.0 |
| HEM | Hemostemix | 0.06 | 0.08 | 0.02 (40.0%) | 29666 | 4.6 | 0.0 | 0.0 |
| VXL | Vaxil Bio | 0.01 | 0.02 | 0.01 (33.5%) | 73521 | 2.1 | 0.0 | 0.0 |
| TH | Theratechnologies | 1.89 | 2.40 | 0.51 (27.0%) | 24374 | 49.8 | 0.0 | 0.0 |
| MRVL | Marvel Biosciences | 0.14 | 0.18 | 0.03 (22.1%) | 42902 | 5.8 | 0.0 | 0.0 |
| RVX | Resverlogix | 0.06 | 0.07 | 0.01 (19.4%) | 24310 | 14.8 | 0.0 | 0.0 |
All data provided as of April 14, 2024.
The list is sorted by stocks with the greatest percentage difference between valuation and price.
Antibe Therapeutics
Antibe Therapeutics Inc is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The company's pipeline includes assets that seek to overcome gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs. Antibe's lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids for post-operative pain.
Antibe Therapeutics is listed under ATE on the Toronto Stock Exchange.
Stockcalc
StockCalc is a Canadian fintech company specializing in fundamental valuations for North American stocks and ETFs.
Stockcalc valuations (https://www.stockcalc.com/Resources) can help determine if a stock is undervalued. Stockcalc’s Weighted Average Valuation (WAV) is based on a proprietary calculation using model and analyst inputs, including:
- Discounted Cash Flow (DCF)
- Price & Other Comparables
- Multiples
- Adjusted Book Value (ABV)
- Analyst Consensus
Artificial Intelligence at Report on Business
Report on Business scans market data using algorithms to process large quantities of information. The results are specialized reports produced through automation. Ongoing ROB project experiments that leverage artificial intelligence include valuation screens across 14 categories and end-of-day Closing Summary reports for all North American securities.
